Heartbeam, Inc. (BEATW) Stock Price & Analysis
Heartbeam, Inc. (BEATW) rose 0.00% to USD 0.01 as of September 9, 2026 at 14:08 UTC, according to Nexqual real-time market data.
BEATW last closed at USD 0.01; the session ranged USD 0.01–0.01 on volume of 5 shares. Market capitalization is —, with a 52-week range of USD 0.01–0.01 (NCM). Source: Nexqual, September 9, 2026 at 14:08 UTC.
Key Statistics (as of September 9, 2026 at 14:08 UTC)
| Price | USD 0.01 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.01 |
| Open | USD 0.29 |
| Day Range | USD 0.01 – 0.01 |
| 52-Week Range | USD 0.01 – 0.01 |
| Volume | 5 shares |
| Market Cap | — |
| Exchange | NCM |
Analyst Ratings (BEATW)
Wall Street analysts rate BEATW "None", per Nexqual as of September 9, 2026 at 14:08 UTC.
| Consensus Rating | None |
|---|
Earnings (BEATW)
| Revenue Estimate | $108,330 |
|---|
Source: Nexqual, September 9, 2026 at 14:08 UTC.
Financial Health Score (BEATW)
Nexqual rates Heartbeam, Inc.'s overall financial health "Mixed" across five dimensions, as of September 9, 2026 at 14:08 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — No data |
| Cash Flow | Mixed — No data |
| Efficiency | Mixed — No data |
Major Backers & Investors (BEATW)
Notable institutional backers of Heartbeam, Inc. include Armistice Capital, LLC, Clear Street Group Inc., D'Orazio & Associates, Inc., according to Nexqual as of September 9, 2026 at 14:08 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Armistice Capital, LLC | 18.18% |
| Clear Street Group Inc. | 0.6% |
| D'Orazio & Associates, Inc. | 0.58% |
| Two Sigma Securities, LLC | 0.42% |
| Wells Fargo & Company | 0.27% |
| UBS Group AG | 0.14% |
Source: Nexqual, September 9, 2026 at 14:08 UTC.
From Heartbeam, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Our ability to develop higher resolution Electrocardiogram ("ECG") solutions is achieved through the development of our proprietary and patented technology platform that allows us to collect the heart's electrical activity from three dimensions and synthesize a 12-Lead ("12L") ECG from these signals.
- As a high-fidelity ECG system, it captures heart signals from three distinct directions for actionable heart health information and allows physicians to diagnose a wide range of non-urgent complex arrhythmias.   HeartBeam device in ready position (left) and the front view(right)   Our patented technology, along with a proprietary algorithm, allows us to generate signals similar to a 12L ECG without the need for cables, unlike a standard 12L ECG machine.
- The VALID-ECG pivotal study was a multicenter trial that enrolled 198 patients across five clinical sites in the US, including Allegheny Health Network, Atlanta Heart Specialists, Mount Sinai Hospital, Northwell Health and Piedmont Heart Institute.
- For some aspects of our proprietary technology, we rely on trade secret protection, while for others we pursue patent protection.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BFRIW | Biofrontera Inc. Warrants | USD 0.02 | ▲ 0% |
| ACONW | Aclarion, Inc. | USD 0.05 | ▲ 0% |
| DRMAW | Dermata Therapeutics, Inc. Warrant | USD 0 | ▼ 50% |
| BFRGW | Bullfrog AI Holdings, Inc. Warr | USD 0.1 | ▼ 1.38% |
| ANGHW | Anghami Inc. Warrants | USD 0.01 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 14:08 UTC. This page is informational and not investment advice.